LncRNA MEG3 Promotes Chemosensitivity of Osteosarcoma by Regulating Antitumor Immunity Via MiR-21-5p/p53 Pathway and Autophagy

Overview

Journal Genes Dis

Date 2023 May 24

PMID 37223512

Authors

Xin Huang

Weiyue Zhang

Feifei Pu

Zhicai Zhang

Affiliations

Soon will be listed here.

Abstract

This study aimed to investigate the role of long non-coding RNA maternally expressed gene 3 (lncRNA MEG3) in chemosensitivity of osteosarcoma (OS), and to reveal the possible underlying mechanisms. In this study, we found that the expression of lncRNA MEG3 was significantly lower in OS tissues and cell lines. Furthermore, lncRNA MEG3 overexpression enhanced chemosensitivity of OS by inhibiting cell proliferation, migration, autophagy, and promoting antitumor immunity. LncRNA MEG3 functioned as miR-21-5 sponge to regulate p53 expression in OS. Mechanically, lncRNA MEG3 promoted OS chemosensitivity by regulating antitumor immunity via miR-21-5p/p53 pathway and autophagy. Collectively, this study provided the evidence that lncRNA MEG3 might be a promising therapeutic target for OS chemoresistance.

Citing Articles

Unraveling the role of long non-coding RNAs in therapeutic resistance in acute myeloid leukemia: New prospects & challenges.

Sharma S Noncoding RNA Res. 2024; 9(4):1203-1221.

PMID: 39036603 PMC: 11259994. DOI: 10.1016/j.ncrna.2024.05.009.

LncRNAs as potential prognosis/diagnosis markers and factors driving drug resistance of osteosarcoma, a review.

Hu S, Han X, Liu G, Wang S Front Endocrinol (Lausanne). 2024; 15:1415722.

PMID: 39015175 PMC: 11249743. DOI: 10.3389/fendo.2024.1415722.

A possible role of lncRNA MEG3 and lncRNA MAFG-AS1 on miRNA 147-b in the pathogenesis of Behcet's disease.

Abobakr S, Shaker O, Hegazy M, Hany A Immunogenetics. 2024; 76(4):233-241.

PMID: 38985298 PMC: 11246302. DOI: 10.1007/s00251-024-01346-8.

Emerging roles of long non-coding RNAs in osteosarcoma.

Liao X, Wei R, Zhou J, Wu K, Li J Front Mol Biosci. 2024; 11:1327459.

PMID: 38516191 PMC: 10955361. DOI: 10.3389/fmolb.2024.1327459.

Chondroitin Polymerizing Factor (CHPF) promotes cell proliferation and tumor growth in human osteosarcoma by inhibiting SKP2's ubiquitination while activating the AKT pathway.

Shen Y, Li J, Peng D, Liao L, Chen X, Zhong W Genes Dis. 2023; 10(5):2125-2136.

PMID: 37492722 PMC: 10363583. DOI: 10.1016/j.gendis.2022.06.010.

References

Waniczek D, Lorenc Z, Snietura M, Wesecki M, Kopec A, Muc-Wierzgon M . Tumor-Associated Macrophages and Regulatory T Cells Infiltration and the Clinical Outcome in Colorectal Cancer. Arch Immunol Ther Exp (Warsz). 2017; 65(5):445-454. PMC: 5602054. DOI: 10.1007/s00005-017-0463-9. View

Mowers E, Sharifi M, Macleod K . Autophagy in cancer metastasis. Oncogene. 2016; 36(12):1619-1630. PMC: 5337449. DOI: 10.1038/onc.2016.333. View

Ma B, Gao Z, Lou J, Zhang H, Yuan Z, Wu Q . Long non‑coding RNA MEG3 contributes to cisplatin‑induced apoptosis via inhibition of autophagy in human glioma cells. Mol Med Rep. 2017; 16(3):2946-2952. DOI: 10.3892/mmr.2017.6897. View

Huang X, Hu H, Zhang W, Shao Z . Prognostic value of prognostic nutritional index and systemic immune-inflammation index in patients with osteosarcoma. J Cell Physiol. 2019; 234(10):18408-18414. DOI: 10.1002/jcp.28476. View

Luetke A, Meyers P, Lewis I, Juergens H . Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat Rev. 2013; 40(4):523-32. DOI: 10.1016/j.ctrv.2013.11.006. View

Liao Y, Yu H, Lv J, Cai Y, Liu F, He Z . Targeting autophagy is a promising therapeutic strategy to overcome chemoresistance and reduce metastasis in osteosarcoma. Int J Oncol. 2019; 55(6):1213-1222. PMC: 6831203. DOI: 10.3892/ijo.2019.4902. View

Ponting C, Oliver P, Reik W . Evolution and functions of long noncoding RNAs. Cell. 2009; 136(4):629-41. DOI: 10.1016/j.cell.2009.02.006. View

Ackermann C, Adderley H, Ortega-Franco A, Khan A, Reck M, Califano R . First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions. Drugs. 2020; 80(17):1783-1797. DOI: 10.1007/s40265-020-01409-6. View

Jin L, Cai Q, Wang S, Wang S, Mondal T, Wang J . Long noncoding RNA MEG3 regulates LATS2 by promoting the ubiquitination of EZH2 and inhibits proliferation and invasion in gallbladder cancer. Cell Death Dis. 2018; 9(10):1017. PMC: 6170488. DOI: 10.1038/s41419-018-1064-1. View

10.

Jiang X, Liu G, Li Y, Pan Y . Immune checkpoint: The novel target for antitumor therapy. Genes Dis. 2021; 8(1):25-37. PMC: 7859424. DOI: 10.1016/j.gendis.2019.12.004. View

11.

Wirawan E, Vanden Berghe T, Lippens S, Agostinis P, Vandenabeele P . Autophagy: for better or for worse. Cell Res. 2011; 22(1):43-61. PMC: 3351915. DOI: 10.1038/cr.2011.152. View

12.

Isakoff M, Bielack S, Meltzer P, Gorlick R . Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. J Clin Oncol. 2015; 33(27):3029-35. PMC: 4979196. DOI: 10.1200/JCO.2014.59.4895. View

13.

Chen L, Wang J, Li J, Zhao X, Tian L . LncRNA MEG3 inhibits proliferation and promotes apoptosis of osteosarcoma cells through regulating Notch signaling pathway. Eur Rev Med Pharmacol Sci. 2020; 24(2):581-590. DOI: 10.26355/eurrev_202001_20034. View

14.

He R, Luo D, Mo Y . Emerging roles of lncRNAs in the post-transcriptional regulation in cancer. Genes Dis. 2019; 6(1):6-15. PMC: 6411652. DOI: 10.1016/j.gendis.2019.01.003. View

15.

Wang P, Chen D, Ma H, Li Y . LncRNA MEG3 enhances cisplatin sensitivity in non-small cell lung cancer by regulating miR-21-5p/SOX7 axis. Onco Targets Ther. 2017; 10:5137-5149. PMC: 5661845. DOI: 10.2147/OTT.S146423. View

16.

Ahadi A . Functional roles of lncRNAs in the pathogenesis and progression of cancer. Genes Dis. 2021; 8(4):424-437. PMC: 8209321. DOI: 10.1016/j.gendis.2020.04.009. View

17.

Mrakovcic M, Frohlich L . p53-Mediated Molecular Control of Autophagy in Tumor Cells. Biomolecules. 2018; 8(2). PMC: 6022997. DOI: 10.3390/biom8020014. View

18.

Huang X, Zhang W, Zhang Z, Shi D, Wu F, Zhong B . Prognostic Value of Programmed Cell Death 1 Ligand-1 (PD-L1) or PD-1 Expression in Patients with Osteosarcoma: A Meta-Analysis. J Cancer. 2018; 9(14):2525-2531. PMC: 6036896. DOI: 10.7150/jca.25011. View

19.

Barbee M, Ogunniyi A, Horvat T, Dang T . Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. Ann Pharmacother. 2015; 49(8):907-37. DOI: 10.1177/1060028015586218. View

20.

White E . The role for autophagy in cancer. J Clin Invest. 2015; 125(1):42-6. PMC: 4382247. DOI: 10.1172/JCI73941. View